攻克 EB-1A 最难关：Final Merits Determination 终审困境与破局之道
Overcoming the EB-1A Final Merits Determination Challenge

在美国首都华盛顿地区，许多在马里兰(Maryland)和弗吉尼亚(Virginia)从事前沿科研、临床医学、人工智能、半导体、生物医药及工程领域的华人申请人都将 EB-1A 杰出人才移民视为最优路径——它无需雇主担保、无需 PERM 劳工证、无需排优先日（中国出生申请人 EB-1 类别仍相对乐观）。然而 2022 年以来，USCIS 对 EB-1A 的审查口径明显收紧，真正的"杀手"不再是 10 条法规标准本身，而是隐藏在第二步的 Final Merits Determination。作为大华府DMV地区的靠谱华人移民律师团队，新未名律所在 RFE 与 NOID 阶段反复成功翻盘，本文系统拆解这道终审难题。

For Chinese researchers, physicians, and STEM professionals across the DMV — Washington D.C., Maryland, and Virginia — EB-1A remains the most attractive employment-based green card route: no employer sponsor, no PERM labor certification, and currently the most favorable priority date posture for China-born petitioners. But since 2022, the real choke point in EB-1A adjudication has shifted from the regulatory criteria to the second-step Final Merits Determination. New Weiming Law Group has repeatedly converted RFEs, NOIDs, and even denials into approvals at this stage.

1. 什么是 Final Merits Determination？为什么它比 3 条标准更难？ / What is the Final Merits Determination, and why is it harder than the three-criteria threshold?

Kazarian v. USCIS（9th Cir. 2010）确立了 EB-1A 两步审理框架：第一步是数 box——看申请人是否至少满足 8 USC 8 CFR §204.5(h)(3) 列举的 10 条标准中的 3 条（或一次性重大国际奖项）；第二步即 Final Merits Determination——审理官需结合整体证据判断申请人是否具备 "sustained national or international acclaim"（持续的全国或国际声誉），并且确实位于该领域 "the very top"（极小一部分顶尖人才）。第一步是客观清单，第二步是高度主观的整体评估，正是当前最难、最不可预测的部分。

Under Kazarian v. USCIS, EB-1A adjudication has two steps. Step one is a checklist: does the petitioner meet at least three of the ten regulatory criteria under 8 CFR §204.5(h)(3), or qualify under a one-time major international award? Step two — the Final Merits Determination — asks whether, on the totality of the evidence, the petitioner has sustained national or international acclaim and is among the small percentage at the very top of the field. Step one is mechanical; step two is highly subjective and is now the dominant cause of EB-1A RFEs, NOIDs, and denials.

2. 为什么"满足 3 条"还会被拒？终审常见的失败模式 / Why do petitions that meet three criteria still get denied?

我们在为 RFE 与 NOID 客户做翻案分析时，反复观察到几个相同的失败模式：(1) 引用证据只有数量、没有"独立第三方实际使用"的因果链；(2) 推荐信清一色合作者出具，缺乏 independent leading experts（独立顶尖专家）的证言；(3) 评审 / 期刊审稿、媒体报道、获奖等 box 虽然打满，但没有把它们与"领域顶尖少数"这一最终命题挂钩；(4) 把 NIW 思路（research has substantial merit）误用到 EB-1A，忽视 EB-1A 要求的是个人地位（personal acclaim），而不是研究方向的国家利益。

In our RFE and NOID rebuttal practice, the same failure patterns recur: citation evidence shown by raw numbers without an independent-use causal chain; recommendation letters dominated by collaborators rather than independent leading experts; box-checking on peer review, media, and awards without tying any of it back to the "very top" question; and conflating NIW logic ("the work matters") with EB-1A logic ("the person is at the top"). EB-1A requires proof of personal acclaim, not just impactful research.

3. 新未名律所如何在初审阶段就为终审"埋好钩子"？ / How does New Weiming Law Group front-load Final Merits arguments at the initial filing?

我们的策略不是"满足 3 条就递交"，而是把整份 I-140 当作一份"已经在做 Final Merits 答辩"的法律文书来撰写。具体体现在：把每一条 box 打勾的同时，立刻补充一段 significance paragraph，解释这条证据为什么直接指向"顶尖少数"；将引用数据转化为独立引用比例、与领域基线对比、被同行 follow-up 使用等可量化叙事；在证据组织上突出 pioneering firsts（首创性突破）、his/her work has been implemented by others（他人实施使用）、critical leadership roles（关键领导角色）、major media coverage（主流媒体报道）、commercial applications（商业化落地）等"硬通货"。这种结构使审理官在第一遍阅读时就同时完成了第一步与第二步的认定。

Our approach is not to "file once three boxes are checked" but to draft the entire I-140 as if Final Merits advocacy were already underway. Every regulatory box is followed by a short significance paragraph tying the evidence to the "very top" standard. Citation data is reframed as independent-citation ratios, field-baseline comparisons, and documented downstream use by other research groups. We foreground the strongest indicators recognized by USCIS — pioneering firsts, implementation of the petitioner's research by others, influential publications, peer-review responsibilities, critical leadership roles, major media coverage, invited presentations, and commercial applications — so that the adjudicator completes step one and step two in the same reading pass.

4. 推荐信怎么写才能真正"撑住"终审？ / What does a Final-Merits-grade recommendation letter look like?

在我们的实务中，推荐信是终审环节最被低估、也最容易"翻盘"的一块证据。普通推荐信只罗列成就，而高质量推荐信必须由独立的领域顶尖专家出具，并具体说明：(a) 申请人解决了什么领域内长期未解的问题；(b) 引入了什么新方法或新范式；(c) 改变了哪些行业实践；(d) 与同领域同侪相比，申请人在哪些维度处于"极小一部分顶尖人才"。这种细节是 Final Merits Determination 中最具说服力的"行业内权威背书"。

Recommendation letters are simultaneously the most undervalued and the most decisive Final Merits evidence. A boilerplate "summary of achievements" letter rarely moves the needle. We work with leading independent experts to produce letters that specifically explain (a) the long-standing field-level problem the petitioner solved, (b) the new methodologies or paradigms the petitioner introduced, (c) how professional practice has shifted as a result, and (d) the dimensions on which the petitioner stands above peers working in the same discipline. This level of specificity is what carries Final Merits weight.

5. 收到 EB-1A RFE 或 NOID 后应该怎么做？ / What should you do after receiving an EB-1A RFE or NOID?

• 逐字解析 USCIS 的法律推理：RFE / NOID 不是"补材料"，而是法律辩论。必须先识别审理官引用的具体法规、政策手册段落（USCIS Policy Manual Vol. 6, Part F）和误判点。
• 证据再分层：把原档案重新切分为"标准 box 证据 + 终审证据 + 独立第三方实证"三层，避免重复堆叠。
• 引入独立专家与客观工具：citation analysis 报告、journal impact 排名、行业权威 ranking、独立 leading experts 的补强信。
• 逐点 rebut + 总体重构叙事：既要对每一个 USCIS 质疑点 one-to-one 反驳，也要在结尾重新陈述"为什么本案在 totality of evidence 下满足 sustained acclaim 与 very top 标准"。
• 评估并行路径：在 RFE / NOID 期间，部分申请人可同步评估 EB-1B、EB-2 NIW 国家利益豁免，必要时构建双线策略，避免单点失败导致整体延迟。

A complete EB-1A RFE/NOID response treats the notice as a legal argument, not a document request. We dissect every legal citation USCIS makes, restructure the record into three tiers (criteria evidence / Final Merits evidence / independent third-party validation), introduce objective tools such as citation analyses and journal rankings plus supplemental letters from independent leading experts, and rebut each USCIS concern one-to-one before reframing the totality-of-evidence narrative. Where appropriate, we evaluate parallel filings under EB-1B (Outstanding Researcher) or EB-2 NIW so a single adverse decision does not derail the petitioner's overall green card timeline.

6. 哪些申请人最应该在递交前做一次终审风险评估？ / Who should run a Final Merits risk assessment before filing?

根据新未名律所在大华府DMV地区处理的案例经验，以下几类申请人务必在递交前做一次 Final Merits 风险评估：早期职业研究人员（pre-tenure / 刚毕业 1–3 年）、引用数中等但 h-index 与领域基线接近的研究者、临床医师与工程师等"成果非论文形态"的申请人、目前以 H-1B、O-1、L-1 或 F-1 OPT 在美工作的申请人、以及曾经收到过 NIW 或 EB-1A RFE 的复杂背景申请人。早一步识别终审弱点，比事后回应 RFE / NOID 节省至少 6–12 个月。

Run a Final Merits risk assessment before filing if you are an early-career researcher, a mid-citation petitioner whose metrics hover near field baselines, a clinician or engineer whose impact does not show up primarily in publications, currently on H-1B, O-1, L-1, or F-1 OPT, or carrying a prior NIW or EB-1A RFE history. Identifying weaknesses pre-filing saves 6 to 12 months over reactive RFE/NOID work.

免责声明 / Disclaimer：本文仅为一般法律资讯与策略分享，不构成针对任何具体个案的法律意见。每个 EB-1A 案件高度依赖证据细节与领域语境，请务必就自身情况单独咨询持牌移民律师。This article is for general informational purposes only and does not constitute legal advice on any specific matter.